RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune
response to and kill papilloma cells.
PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating
young patients with recurrent papilloma of the larynx.
OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the
larynx treated with autogenous vaccine derived from each patient's own tumor.
OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously
weekly for 20 weeks.
PROJECTED ACCRUAL: Not specified
DISEASE CHARACTERISTICS: Diagnosis of severe recurrent juvenile papilloma of the larynx
requiring surgery at least 4 times per year Condition must have existed for more than 1
PATIENT CHARACTERISTICS: Age: 1 and over Performance status: Not specified Life expectancy:
Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
PRIOR CONCURRENT THERAPY: See Disease Characteristics